Clinical trial
Study of the Safety and Immune Response of Two Serogroup B Meningococcal…
NCT00297817 · Novartis Vaccines, Industry · Completed
Key facts
| NCT number | NCT00297817 |
|---|---|
| Title | Study of the Safety and Immune Response of Two Serogroup B Meningococcal Vaccines Administered to Healthy Adolescents |
| Official title | A Phase 2, Single-Blind, Controlled, Randomized Study of the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine ± OMV When Administered at an 0-2-6-Month Schedule in Healthy Adolescents 11-18 Years of Age |
| Lead sponsor | Novartis Vaccines, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Meningococcal Disease |
| Intervention type | Biological |
| Interventions | serogroup B meningococcal vaccine |
| Enrollment | 203 |
| Start date | Feb 1, 2006 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Mar 1, 2006 |
| Last update posted | Dec 1, 2016 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: